NEW YORK (GenomeWeb News) — Nasdaq has notified Tripos that it can be delisted from the Nasdaq Global Market and from the Nasdaq Stock Market because it has become a “public shell” after selling its Discovery Research and Discovery Informatics branches.
 
Tripos, which said it has been anticipating the notice, said it will meet with the exchange June 28 to review the matter.
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.